Loading...

NEXGEL, Inc.

NXGLNASDAQ
Healthcare
Medical - Instruments & Supplies
$2.38
$0.16(7.23%)

NEXGEL, Inc. (NXGL) Financial Performance & Income Statement Overview

Review NEXGEL, Inc. (NXGL) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
112.47%
112.47%
Operating Income Growth
-2.21%
2.21%
Net Income Growth
-3.93%
3.93%
Operating Cash Flow Growth
-19.50%
19.50%
Operating Margin
-26.06%
26.06%
Gross Margin
38.26%
38.26%
Net Profit Margin
-25.02%
25.02%
ROE
-57.47%
57.47%
ROIC
-41.59%
41.59%

NEXGEL, Inc. (NXGL) Income Statement & Financial Overview

Explore comprehensive income reports for NEXGEL, Inc. NXGL, broken down by year and quarter.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$3.04M$2.94M$1.44M$1.27M
Cost of Revenue$2.26M$1.66M$1.03M$1.02M
Gross Profit$779000.00$1.28M$410000.00$246000.00
Gross Profit Ratio$0.26$0.44$0.28$0.19
R&D Expenses$0.00$0.00$76000.00$2000.00
SG&A Expenses$1.53M$2.07M$1.39M$1.11M
Operating Expenses$1.62M$2.07M$1.46M$1.12M
Total Costs & Expenses$3.88M$3.73M$2.49M$2.14M
Interest Income$0.00$0.00$1000.00$0.00
Interest Expense$16000.00$20000.00$30000.00$15000.00
Depreciation & Amortization$150000.00$184000.00$86000.00$114000.00
EBITDA-$698000.00-$554000.00-$863000.00-$776000.00
EBITDA Ratio-$0.23-$0.19-$0.60-$0.61
Operating Income-$841000.00-$788000.00-$1.05M-$871000.00
Operating Income Ratio-$0.28-$0.27-$0.73-$0.69
Other Income/Expenses (Net)$17000.00$34000.00$75000.00-$34000.00
Income Before Tax-$824000.00-$754000.00-$979000.00-$905000.00
Income Before Tax Ratio-$0.27-$0.26-$0.68-$0.71
Income Tax Expense$0.00$0.00$0.00-$52000.00
Net Income-$850000.00-$693000.00-$885000.00-$853000.00
Net Income Ratio-$0.28-$0.24-$0.61-$0.67
EPS-$0.13-$0.11-$0.14-$0.14
Diluted EPS-$0.13-$0.11-$0.14-$0.14
Weighted Avg Shares Outstanding$7.30M$6.57M$6.25M$5.98M
Weighted Avg Shares Outstanding (Diluted)$7.30M$6.57M$6.25M$5.98M

The company's financials show resilient growth, with revenue advancing from $1.27M in Q1 2024 to $3.04M in Q4 2024. Gross profit remained healthy with margins at 26% in Q4 2024 compared to 19% in Q1 2024. Operating income hit -$841000.00 last quarter, sustaining a consistent -28% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$698000.00. Net income dropped to -$850000.00, while earnings per share reached -$0.13. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;